On the Watch
The role of pharmacists evolving in the team-based approach to medical care
Pharmacists can play an influential role in ensuring patient access to quality health care by both encouraging and enhancing patient medication adherence and increasing patient knowledge of their disease states and medication therapies.
On the Watch
Drugs in Context: Farxiga
Antidiabetic drugs are considered to be first-line treatment options for individuals with type 1 and type 2 diabetes mellitus. It is estimated that type 2 diabetes affects about 24 million persons in the United States. Over time high blood levels can
previous pause next
  • Hospira scores temporary win in lawsuit versus FDA

  • Precedex, dexmedetomidine hydrochloride, is approved to sedate patients with breathing tubes in an intensive-care setting, as well as patients without breathing tubes before and during surgeries and other procedures. Hospira’s patent that covers the use of Precedex in an intensive-care setting in due to expire in 2019, however other patents have already expired. On Monday, the FDA approved the sale of generic copies of the drug as long as the companies leave out information from the prescribing labels about uses that are covered under Hospira’s patent, including “intensive-care unit sedation.”
  • FDA approves apixaban for treatment of DVT, PE

  • FDA has approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE.
  • FDA approves Arnuity Ellipta for asthma

  • FDA has approved fluticasone furoate inhalation powder (Arnuity Ellipta, GlaxoSmithKline) for maintenance treatment of asthma in patients aged 12 years and older.
  • FDA approves new multiple sclerosis drug

  • FDA has approved peginterferon beta-1a (Plegridy, Biogen Idec) for the treatment of adults with relapsing forms of multiple sclerosis (MS).
  • New drug approved to treat a form of Gaucher disease

  • FDA has approved eliglustat (Cerdelga, Genzyme), the only first-line oral therapy for the long-term treatment of adults with the Type 1 form of Gaucher disease.
More Articles